Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
  • A61K36/07—Basidiomycota, e.g. Cryptococcus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P19/00—Preparation of compounds containing saccharide radicals
  • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention is directed to a method for producing an immune stimulant in liquid culture.
• the invention is in one embodiment directed to culturing Lentinus edodes under particular conditions in a fermentation broth.
• This application is a non-provisional claiming priority from Norwegian patent application No. NO 2001 4256 filed 3 Sep. 2001, which is hereby incorporated by reference in its entirety. All patent and non-patent references cited in that application, or in the present application, are also hereby incorporated by reference in their entirety.
• Lentinus edodes One active ingredient of Lentinus edodes is termed lentinan, a polysaccharide based compound described as a beta-(1,3) glucan backbone with beta-(1,6) side chains.
• Solid-state reactors are routinely used for culturing fungi such as Lentinus edodes . This is a technology which is used for many purposes such as composting, production of biological products such as enzymes, soy sauce, acetic acid, and the like.
• Lentinus edodes can be cultivated on a suitable solid matrix provided by stems of tree or chips of wood to which is often added chemical compounds supporting the growth of mycelium and development of the fruiting bodies, where most of the lentinan is localised.
• the fruiting bodies are harvested, either by hand or mechanically, and are subsequently dried and ground to a powder which can be used as it is, or used in tablets, or sent for further processing such as extraction of lentinan.
• the methods used for culturing fungi such as Lentinus edodes, harvesting and subsequently drying the fruiting bodies, and optionally extraction of lentinan, are well known for the skilled person.
• the cultivation time can be from four to ten weeks with few possibilities for controlling the process. This results in a fungal growth, and in turn, in an amount of lentinan produced which is not the same for each batch carried out. Also, extraction of lentinan from the fungal material is time consuming and process intensive.
• Kim et al. (2001, Biotechnology Letters, 23, 513-517) describes extracellular polysaccharides produced by Phellinus lintus in submerged culture; Kim et al. (2002: Letters in Applied Microbiology, 34, 56-61) describes mycelial growth and exobiopolymer production by submerged culture of various edible mushrooms. There is no data available to indicate that any of these extracellular polymers are immune stimulating.
• the invention in a first aspect, relates to a method for cultivating a fungal mycelium, preferably a fungus from the class of basidiomycetes, such as a fungus of the genus Lentinus, such as Lentinus edodes, in a liquid medium of sterile water to which nutrient compounds are added in predetermined concentrations.
• the liquid medium supports fungal growth and stimulates the production of extracellular compounds, such as immune stimulating agents, such as lentinan produced by fungal mycelium of the genus Lentinus, such as e.g. Lentinus edodes.
• fungal mycelium any fungal biomass, which can be grown in submerged culture according to the invention.
• the fungal biomass may be in the form of single hyphae, spores, aggregates of mycelium, and partly differentiated mycelium.
• Lentinan refers to the polysaccharide, which can be isolated from Lentinus edodes (Berk.) Sing.
• the primary structure is a ⁇ -1,3-D-glucan having 2 ⁇ -1,6-glucopyranoside branchings for every 5 ⁇ -1,3 linear linkages.
• the molecular weight may vary from 400,000 to 800,000 (Merck Index 12 th Edition, 1996, Monograph No 5462).
• the cultivation of the fungal mycelium results in the production of one or more extracellular agents, such as e.g. immune stimulating agents, in the form of e.g. a polysaccharide, such as e.g. a beta-glucan, including lentinan isolatable from Lentinus edodes, a polypeptide, a glycosylated polypeptide or a proteinacious polysaccharide compound, a proteoglucan, such as e.g.
• a polysaccharide such as e.g. a beta-glucan
• lentinan isolatable from Lentinus edodes a polypeptide, a glycosylated polypeptide or a proteinacious polysaccharide compound
• a proteoglucan such as e.g.
• a polypeptide associated alpha-glucan or a polypeptide associated alpha-mannan including KS-2 isolatable from Lentinus edodes, a lipid, or a secondary metabolite, which can be isolated and/or purified, and optionally fractionated, from the extracellular fraction of the fermentation broth of a bioreactor following cultivation of the basidiomycete fungal mycelium in question.
• the extracellular fraction of the liquid fermentation medium is also termed the supernatant and this fraction can be separated from the fungal mycelium by e.g. centrifugation or filtration, or indeed by any other means available for obtaining a liquid fraction essentially without any fungal mycelium present therein.
• the term “essentially without any fungal mycelium present therein” shall denote that the concentration of fungal mycelium, including fractions thereof, has been reduced at least by a factor of 10 3 , such as reduced by a factor of at least 10 4 , for example a factor of at least 10 5 , such as reduced by a factor of at least 10 6 .
• fungal extracellular agents such as immune stimulating agents according to the present invention are surprisingly more potent than fungal associated agents, i.e. agents being either fungal intracellular agents, or agents which are removed from a liquid fermentation broth along with the removal of the fungal mycelium and fractions thereof by filtration, precipitation, or otherwise.
• the invention relates to an immune stimulating agent obtainable from the extracellular part of the liquid growth medium according to the method of producing said immune stimulating agent.
• This immune stimulating agent has surprisingly turned out to have a higher immunostimulating activity than the corresponding extract obtainable from the mycelium of the fungus, although the mycelium is known as the primary source of e.g. lentinan.
• this extract is obtainable by removal of mycelium, removal of water from the medium, one or more rounds of precipitation with alcohol and washing with acid and/or base.
• composition comprising the immune stimulating agent obtainable as described above and a physiologically acceptable carrier.
• a pharmaceutical composition comprising the immune stimulating agent according to the invention and a pharmaceutically acceptable carrier.
• the pharmaceutical composition may in particular be used for treatment or prophylaxis in connection with an immune compromised condition.
• Fungi belonging to the genus of Lentinus represent one example of fungi according to the present invention.
• the fungus is selected from the group of fungi consisting of Auricularia auricula - judae, Coriolus versicolor, Grifola frondosa, Flammulina velutipes, Schizophyllum commune, Sclerotinia scleroticum, Trametes versicolor, Tremella fuciformis, Agaricus blazei, Cordyceps sinensis, Ganoderma lucidum, Hericium erinaceus, lonotus obliquus, Pleurotus ostreatus, and Polyperus umbellatus.
• liquid-state cultivation of Lentinus mycelium, or fractions thereof is used.
• this involves dissolving in water the nutrient compounds a microbial organism such as fungal mycelium, or fractions thereof, require for growth, transferring the solution to a bioreactor and inoculating the bioreactor with cells or spores of the microbial organism such as a fungal mycelium, or fractions thereof, to be cultivated. This is done under sterile conditions and with control of the environment in order to give the microbial organism a suitable chemical and physical environment.
• the technology related to “liquid-state” cultivation of microbial organisms is well known for the skilled person.
• liquid-state as compared to “semi-solid-state” or “solid-state” cultivation is that “liquid-state” proceeds more rapidly, is more effective with respect to conversion of the raw materials to products, and most importantly, it offers greater possibilities for controlling the growth conditions and thereby the reproducibility and the predictability of the process.
• the various “liquid-state” processes are the microbial organisms which are used and the cultivation conditions.
• the microbial organism will be Lentinus edodes which is cultivated under the conditions described below.
• the medium with the fungal biomass is preferably agitated to reduce the occurrence of gradients and to ensure oxygen availability to the submerged cells.
• oxygen may be supplied to the liquid medium and the level of dissolved oxygen may be controlled by known methods.
• a method for production of lentinan characterised by cultivating mycelium from Lentinus edodes in a liquid growth medium comprising one or more typical ingredients required for growth of microbial organisms such as malt extract, yeast extract, peptone, glucose, sucrose, salts providing phosphate, magnesium and potassium, corn-steep liquor and vitamins such as thiamine. More preferably, the medium comprises malt extract, yeast extract, peptone and glucose for mycelium growth and production of lentinan.
• Lentinus edodes mycelium from agar plates containing malt extract, yeast extract, peptone and glucose can be used. Lentinus edodes can initially be cultivated on agar plates comprising the above nutrient compounds supporting the growth of the fungus.
• the plates are inoculated with mycelium from Lentinus edodes and incubated at least until a visible growth is evident on the plates, this can take from about 7 days to about 24 days or from about 10 to 30 days, typically 14 days or up to 20 days, at a temperature in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
• the temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
• inoculation of the growth medium can be carried out by using Lentinus edodes mycelium from a fermentation broth in e.g. a shake flask medium comprising nutrient compounds supporting cell growth.
• Shake flasks for cultivating Lentinus edodes can initially be inoculated with the mycelium which is cultivated on agar plates. The mycelium is scraped off the plates and transferred aseptically to shake flasks containing sterile water comprising dissolved nutrient compounds and nutrient salts supporting the growth of the fungal mycelium.
• a typical growth medium contains glucose, peptone, yeast extract and malt extract. The amount of inoculation material which gives the highest production of extracellular lentinan can be selected following initial experiments.
• the shake flasks can be incubated by shaking for 6 to 21 days, preferably from 7 to 18 days, more preferably from 8 to 14 days at a temperature in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
• the shake flasks may also be incubated from 8-25 days, more preferably from 10-20 days, more preferably from 12-18 days.
• the temperature may also be from 18 to 37° C., preferably from 23 to 32° C such as about 28° C.
• the content of the shake flasks can be used for inoculating a bioreactor.
• the reactor comprises a sterile solution of nutrient compounds and nutrient salts in water for mono-culture cultivation of basidiomycete fungal mycelium, or fractions thereof, such as Lentinus fungal mycelium, such as Lentinus edodes.
• the bioreactor fermentation period is typically in the range of from 50 hours to 300 hours, preferably in the range of from 80 hours to 270 hours, and the temperature is kept constant in the range of 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
• the temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
• the reactor is fitted with an inlet for supplying air to the fermentation broth, and the fermentation broth is preferably kept under continuous agitation either as a result of the addition of air, or by means of a mixer device suitable for providing a good mixing of the content of the reactor.
• the pH of the growth medium is adjusted to from about 3 to about 7, such as a pH of from about 4.5 to about 6.5, for example a pH of about 6, before the growth medium is inoculated with fungal mycelium, or fractions thereof, such as L. edodes mycelium.
• pH may be dropped naturally during the course of the fermentation, or controlled at a particular value in the range pH 3 to 7, using addition of suitable pH-control agents, such as acid and base.
• the temperature of the growth medium is preferably in the range of from 18 to 32° C., preferably in the area of from 22 to 31° C., such as a temperature of about 23° C., for example 24° C., such as 25° C., for example 26° C., such as 27° C., for example 28° C., such as 29° C., for example 30° C.
• the temperature may also be from 18 to 37° C., preferably from 23 to 32° C. such as about 28° C.
• Samples can be obtained from the bioreactor and analysed for biomass, metabolic products and nutrient compounds, the determinations of which can assist the operator of the bioreactor in the running of the fermentation process.
• Typical analyses routinely carried out are determination of biomass, residual sugar concentration and extracellular agent concentration, such as lentinan concentration in the case of Lentinus including Lentinus edodes.
• a person skilled in the art knows the methods for analysis which can be employed in this respect.
• extracellular lentinan may be removed from the liquid growth medium by precipitation with e.g. alcohol, or by other means which result in the isolation and/or purification of microbial polysaccharides. It is an important aspect of the present invention that such isolation from the growth medium is performed with gentle methods and is generally carried out at temperatures around room temperature. Therefore the extracted compounds are not degraded or converted as may often be the case when using harsh extraction conditions for extracting compounds from the mycelium or from the fruiting bodies of Lentinus edodes.
• ATCC American Type Culture Collection, P.O.Box 1549, Manassas, Va.
• CBC Cetraalbureau voor Schimmelcultures, PO Box 85167, 3508 AD Utrecht, THE NETHERLANDS
• DSMZ Deutsche Sammiung von Mikroorganismen und Zelikulturen GmbH, Mascheroder Weg 1b, 38124 Braunschweig GERMANY.
• an immune stimulating agent preferably a polysaccharide or a glycosylated polypeptide, obtained from the cultivation of basidiomycete fungal mycelium such as Lentinus mycelium according to the method of the invention.
• an extracellular agent such as lentinan in a method for stimulating the immune system of an individual in need of such stimulation.
• the lentinan is administered e.g. orally or subcutaneously to the individual in a pharmaceutically effective amount capable of stimulating the immune system of the individual.
• the stimulation of the immune system can be demonstrated by e.g. increased antibody production, by activation of helper T-cells, or by increased production of interleukins such as Interleukin 1 and Interleukin 2.
• an extracellular agent such as lentinan in the manufacture of a medicament for treating an immune compromised condition in an individual in need of such treatment.
• An immune compromised condition in an individual is demonstrated e.g. by an insufficient amount of antibodies, or a decreased antibody production, by an insufficient amount of helper T-cells, or a decreased production of helper T-cells in the individual, or by an insufficient amount of interleukins such as Interleukin 1 and Interleukin 2, or a decreased production of interleukins such as Interleukin 1 and Interleukin 2 in the individual.
• “Insufficient amount” and “decreased production” as used herein above shall denote such amounts and productions which a medical expert considers as being below a predetermined level or value normally associated with a healthy individual. The amount and/or production will generally depend on factors such as age, general physical condition, and the like. For this reason a predetermined level or value shall be determined on an individual basis by a medical expert.
• One indication of an immune compromised condition in an individual is a gradually decreasing number of antibodies, a gradually decreasing number of CD4 (positive) cells, or a gradually decreasing number of T-helper cells per unit (blood) sample volume measured over time, such as days, weeks, months or years.
• extracellular immunostimulants includes, but is not limited to, ⁇ -(1,3), ⁇ -(1,6) D-glucans, schizophyllan, grifolan, coriolan and Coriolus versicolor glycosylated polypeptides such as PSK and PSP, polypeptides associated with alpha-mannan such as KS-2 isolatable from Lentinus edodes, and reishi isolatable from Ganoderma lucidum.
• Table 1 herein below for a further detailed description of the structure and composition of the above extracellular immunostimulants.
• Preferred immunostimulating agents produced by fungal mycelium of the invention are polysaccharides such as polysaccharides comprising a ⁇ -D-glucan backbone (i.e. linear polymers of D-glucose with other monosaccharides), or ⁇ -D-glucans linked to proteins (so-called polysaccharide-peptides, or “proteoglucans”).
• the preferred polysaccharides are homopolymers.
• the basic ⁇ -D-glucan is a repeating structure with its D-glucose molecule joined by linear chains by ⁇ -bonds from the carbon 1 of one saccharide ring to the carbon 3 of the next ( ⁇ -1,3), from carbon 1 to carbon 4 ( ⁇ -1,4), or from carbon 1 to carbon 6 ( ⁇ -1,6).
• the best know immune. stimulating compound produced by Lentinus edodes is lentinan. This is ⁇ -(1,3) D-glucan with ⁇ -(1,6) side chains.
• the chain length varies with the typical product having a molecular weight in the range 400,000 -1,000,000 g/mol. Further preferred polysaccharides are listed in Table 1.
• an extracellular agent such as e.g. lentinan
• 12 weeks old Sprague Dawley rats receive 1 mg of test compound which have been extracted from the fermentation broth in 0.5 ml 0.09 saline (i.p.) 2 days before the immunisation.
• Control animals receive 1 mg casein.
• the animals are immunised with BSA (0.5 mg) in 0.25 “Freunds Complete Adjuvant” and blood samples are obtained after 11 days for measurement of the antibody response.
• the specific anti-BSA antibody concentration is determined against an absolute standard of antibody BSA by means of “sandwich” ELISA.
• a typical result of the immuno-stimulating activity of intracellular and extracellular lentinan is shown in Table 7a and 7b.
• Further additional preferred embodiments of the present invention relate to extracellular agents, other than immunostimulating agents, produced by a number of fungi, as well as to methods for producing said agents and methods for using said agents.
• the fungi of particular interest to the present invention include Lentinus edodes, Ganoderma lucidum, Auricularia auriculajudae, Coriolus versicolor, Grifola frondosa, Flammulina velutipes, Schizophyllum commune, Sclerotinia scleroticum, Trametes versicolor, Tremella fuciformis, Agaricus blazei, Cordyceps sinensis, Ganoderma lucidum, Hericium erinaceus, lonotus obliquus, Pleurotus ostreatus, and Polyperus umbellatus.
• the above fungal mycelium can be cultivated in mono-culture in a bio-reactor under suitable growth conditions allowing growth and propagation of the fungal mycelium in question.
• the growth conditions cited herein for Lentinus edodes can also be used for the above fungal mycelium.
• extracellular fungal immune stimulating agents such as extracellular proteinacious compounds, including glycosylated polypolypeptides, such as the alpha-mannan polypeptide KS-2, and extracellular polysaccharides, such as extracellular lentinan produced by Lentinus edodes
• extracellular fungal immune stimulating agents such as extracellular proteinacious compounds, including glycosylated polypolypeptides, such as the alpha-mannan polypeptide KS-2, and extracellular polysaccharides, such as extracellular lentinan produced by Lentinus edodes
• the fungal microbial organisms of the invention such as e.g.
• the polysaccharide chains are true glucans, mainly 1,4; 1,2 and 1,3 glucose linkages Lentinus edodes KS-2 Polypeptide associated ⁇ -mannan Lentinus edodes lentinan ⁇ -(1,3), ⁇ -(1,6) D glucan Ganoderma lucidum reishi
• the basic structure of the major bioactive Ganoderma glucans ⁇ - (1,3), ⁇ -(1,6) D glucan is ⁇ -(1,3)D- glucopyronan with 1-5 units of ⁇ - (1,6) monoglucosyl side chains
• the effects associated with the above extracellular agents produced by the fungi of the invention are e.g. analgesic effects, anti-allergic activity, bronchitis-preventative effects, anti-inflammatory activity, anti-bacterial properties (against Staphylococci, Streptococci and Bacillum pneumoniae ), antioxidant effects, antitumor activity, blood pressure lowering effects, bone marrow formation enhancing effects, cardiotonic activity (i.e.
• the invention relates to a method of treatment of an individual diagnosed with an immune compromised condition, said method comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating said immune compromised condition.
• the administered amount may in be an amount effective in prophylactically treating said immune compromised condition.
• a method of treatment of an individual diagnosed with or at risk of contracting acquired immunodeficiency syndrome comprising the steps of administering to said individual the composition according to the invention or the pharmaceutical composition according to the invention in an amount effective in treating or prophylactically treating said syndrome.
• the immune compromised condition may be selected from the group consisting of an infectious disease, a parasitic disease, haemophilus meningitis, pneumococcal meningitis, streptococcal meningitis, staphylococcal meningitis, meningitis due to other organisms, encephalitis, viral pneumonia, pneumococcal pneumonia, other bacterial pneumonia, pneumonia due to other specified organisms except bacteria, bronchopneumonia, organism unspecific pneumonia, influenza, unspecified diarrhea, hepatitis unspecified, acute and subacute necrosis of the liver, chronic hepatitis, and abscess of liver.
• the immune compromised condition may be an infectious or parasitic disease caused by, or selected from, cholera, salmonella, shigellosis, Escherichia coli, intestinal infection due to other specified bacteria, Clostridium difficile, viral gastroenteritis, infectious colitis, enteritis and gastroenteritis, infectious diarrhea, tuberculosis, listeriosis, pasteurellosis, mycobacterium, diphtheria, pertussis, meningococcus, streptococcus septicaemia, staphylococcus septicaemia, pneumococcal septicaemia, septicaemia due to anaerobes, septicaemia due to other gram-negative organisms, actinomycotic infection, gas gangrene, toxic shock syndrome, necrotizing faciitis, Friedlander's bacillus, haemophilus influenzae, pseudomonas, AIDS/HIV infections, acute poliomyelitis, Creutzfeldt-Jacob disease, suba
• the individual may be a mammal including a human being.
• the pharmaceutical composition according to the invention may also be used in the manufacture of a medicament for treatment of an immune compromised condition of an individual in need of such treatment.
• the immune-compromised condition may be any of those disclosed above.
• the treatment may be prophylactic, ameliorating or curative.
• compositions and the pharmaceutical compositions according to the invention may also form part of a kit comprising said compositions and a dosage regime instruction with guidelines for dose and time administration.
• the extracellular agents such as e.g. lentinan can be isolated from the extracellular growth medium following a fermentation of e.g. Lentinus fungal mycelium, or part thereof, in a liquid growth medium.
• Isolation can occur by alcohol precipitation using 70% alcohol or 96% alcohol.
• Suitable alcohols are C1 to C5 aliphatic alcohols, such as methanol, ethanol, propanol, iso-propanol, n-butanol, iso-butanol, n-pentanol.
• the ratio between the volume of extracellular growth medium and alcohol can vary from 5:1 to 1:5, such as 4:1, 3.1, 2:1, 1:1, 1:2, 1:3, 1:4, and 1:5 depending on the concentration of alcohol and the length of the carbon chain.
• a fraction of such agents including polysaccharides
• Desalting can be carried out using a suitable column or by dialysis; suitable acidic solutions are diluted strong acids having a pH of from about 1 to about 7, such as a pH of from about 2 to about 6; suitable basic solutions are diluted strong bases having a pH of from about 7 to about 11, such as a pH of from about 8 to about 10.
• Weak acids and weak bases can also be used for the washing step, as can 70% ethanol when e.g. 96% ethanol has been used for the precipitation.
• Ion exchange chromatography and/or gel filtration are preferably used after desalting and/or washing of the precipitate.
• fractions comprising extracellular agents having a molecular weight of from about 10,000 g/mol to about 20,000 g/mol, extracellular agents having a molecular weight of from about 20,000 g/mol to about 40,000 g/mol, extracellular agents having a molecular weight of from about 40,000 g/mol to about 60,000 g/mol, extracellular agents having a molecular weight of from about 60,000 g/mol to about 80,000 g/mol, extracellular agents having a molecular weight of from about 80,000 g/mol to about 100,000 g/mol, extracellular agents having a molecular weight of from about 100,000 g/mol to about 150,000 g/mol, extracellular agents having a molecular weight of from about 150,000 g/mol to about 200,000 g/mol, extracellular agents having a molecular weight of from about 200,000 g/mol to about
• the purification can also involve steps actively seeking to remove e.g. proteinacious substances from e.g. a polysaccharide fraction. This can be achieved by proteolytic degradation by e.g. proteinase K. Lipids can be removed from a fraction by treatment with lipase or esterase. Undesirable polysaccharides can be removed by treatment with enzymes such as glucanases, amylases, and the like.
• the purity of an isolated fraction of extracellular agents can be determined by e.g. chromatography or spectroscopy.
• a medium composed of glucose, malt extract, yeast extract and peptone in various concentrations was used for cultivating Lentinus edodes for achieving fungus growth and lentinan production in 500 ml shake flasks containing 200 ml of medium.
• the content of the various media is shown in Table 2. The flasks were shaken for 16 days at 28 degrees Centigrade.
• the present results show that by changing the amount of inoculation material used and the composition of the fermentation medium, it is possible to affect the growth of Lentinus edodes and lentinan production.
• the present experiments were carried out in a 10-litre reactor but there is no reason for restricting the process to the mentioned size.
• the medium may contain malt extract, yeast extract, peptone and glucose.
• the results show that there may be a relation between medium composition and production of lentinan.
• the first filtrate after the fermentation went though the same steps from reducing the volume by boiling onwards.
• the only step the extracellular product did not go through was being kept at 121° C. for two hours.
• lentinan is a very active stimulator of the immune system.
• the extracellular product provides a higher response than intracellular lentinan. It is, therefore, desirable to optimise the fermentation process for the production of extracellular lentinan. Extraction of intracellular lentinan is costly with respect to time, personnel and chemicals. It is, however, very simple to remove the extracellular product from the fermentation broth as methods for the precipitation of a polysaccharide can be used, for example by means of various types of alcohol.
• a medium composed of 15 g/l glucose, 3 g/l malt extract, 3 g/l yeast extract and 5 g/l peptone was used for cultivating Lentinus edodes to obtain fungus growth and lentinane production in 500-ml shake flasks containing 200 ml of medium. The flasks were shaken at 28 degrees Centigrade for a given number of days and the concentration of biomass and lentinan, respectively was measured. Typical results are given in Table 7 given below. TABLE 7 Shake Flask Experiments Biomass Extracellular Product Fermentation time (g/l) (g/l) (days) 1.33 65 14 5.0 53 22
• the experiments were carried out in a 3-litre and a 10-litre bioreactor with stirring equipment.
• the reactor was sterilized and filled with 2 and 6 litres of sterile medium, respectively.
• the reactor was inoculated with the content of 7-8 days old shake flasks. Air was supplied to the reactors and the stirring equipment performed a good mixing of the reactor content.
• the temperature was kept at 28 degrees Centigrade. In the experiments reported here, the fermentation time was 7 days unless otherwise stated.
• the concentration of biomass dry weight
• the concentration of isolated dried polysaccharide can be 200 mg/I.
• Typical results are given in Table 2. TABLE 8 Typical Results from Bioreactor Experiment Biomass Extracellular Product (g/l) (mg/l) Comments 2.5 100 Glucose-based medium 1.6 140 Sucrose-based medium

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Mycology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• General Engineering & Computer Science (AREA)
• Alternative & Traditional Medicine (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (4)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (2)

Publications (1)

Family

ID=19912789

Family Applications (5)

Family Applications After (4)

Country Status (5)

Cited By (8)

Families Citing this family (15)

Citations (55)

Family Cites Families (53)

• 2001
  • 2001-09-03 NO NO20014256A patent/NO20014256D0/no unknown
• 2002
  • 2002-09-03 WO PCT/IB2002/003557 patent/WO2003020944A2/fr not_active Ceased
  • 2002-09-03 US US10/488,427 patent/US20050163800A1/en not_active Abandoned
  • 2002-09-03 AU AU2002328099A patent/AU2002328099A1/en not_active Abandoned
  • 2002-09-03 EP EP02762662.1A patent/EP1451336B1/fr not_active Expired - Lifetime
• 2005
  • 2005-12-19 US US11/305,136 patent/US20060094689A1/en not_active Abandoned
• 2010
  • 2010-10-01 US US12/896,726 patent/US8758768B2/en not_active Expired - Lifetime
• 2014
  • 2014-01-23 US US14/162,272 patent/US9249438B2/en not_active Expired - Fee Related
• 2016
  • 2016-01-28 US US15/008,891 patent/US10471135B2/en not_active Expired - Fee Related

Patent Citations (69)

Also Published As

Similar Documents

Legal Events